Wie kann man Schüler optimal fördern? Welche Lernmethoden und Unterrichtsstrategien funktionieren wirklich? Auf Basis pädagogisch-psychologischer Erkenntnisse liefert dieser Band praxistaugliche Antworten. Er stellt Ergebnisse der Unterrichtsforschung vor, diskutiert Qualitätsmerkmale und gibt Tipps zur Gestaltung des eigenen Unterrichts. Fallbeispiele und Übungen helfen Studenten, Referendaren und Lehrern bei der Umsetzung in die Praxis.
Background The aim of this study was to evaluate the dosimetry for [177Lu]Lu-PSMA-617 in advanced non-prostate cancer (non-PCa) patients with previous intense radiotracer uptake of the tumor lesions on PET/CT using [68Ga]Ga-PSMA-11. Results Dosimetry data of 5 patients with non-prostate cancer (non-PCa group) were assessed and compared; Non-PCa tumors were breast cancer (BC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and anaplastic astrocytoma (AA). Five patients with metastatic castration-resistant prostate cancer (PCa group) were used as control-group. All patients were given [177Lu]Lu-PSMA-617 after proven sufficient PSMA uptake of tumor lesions by [68Ga]Ga-PSMA-11 PET/CT. Post-therapeutic dosimetry with serial whole-body scans (24, 48 and 72-120 h post-injection) included calculation of effective half-life and absorbed doses for tumor and non-tumor lesions and comparison between non-PCa and PCa patients. The mean effective half-life in tumor lesions was significantly shorter in non-PCa compared to PCa patients (27.1 +/- 13.1 h vs. 74.9 +/- 23.1 h, respectively, p < 0.001). Likewise, the mean absorbed dose per injected activity was significantly lower in tumor lesions of non-PCa compared to PCa (0.49 +/- 0.40 Gy/GBq vs. 3.51 +/- 2.20 Gy/GBq, respectively, p < 0.001). No significant differences for the source organ absorbed dose or effective half-life were observed between both groups. Conclusions In non-prostate malignancy with impressive diagnostic PSMA-mediated tumor uptake, i.e. high tracer uptake at early time points in [68Ga]Ga-PSMA-11 PET/CT, [177Lu]Lu-PSMA-617 delivers a low tumor-absorbed dose due to a short effective half-life, therefore this therapy does not appear to be a potential antitumor option.
The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, most recently updated in 2022, incorporate recent advances in genomic testing, disease detection methods, target identification, and response assessment. Whilst similarities exist between AML in children and adults, pediatric AML is frequently characterized by unique cytogenetic and molecular features, which require distinct genetic and immunophenotypic diagnostics, therapeutic approaches, response assessment criteria, and supportive care strategies. To address these specific needs, an international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine scientists convened to develop recommendations for the diagnosis and management of AML in children, adolescents, and young adults (hereafter termed pediatric AML) that are discussed in this special report.
We combine a large-scale field experiment with a customized survey to study how consumers use and respond to ESG disclosure. In a sample of over 24,000 U.S. households, we first establish that while consumers moderately prefer to purchase from ESG-responsible firms, they rarely consult corporate reporting directly and face various frictions in learning about firm-level activities. In our field experiment, we then inform households about real firm-disclosed activities through several randomized information treatments. Consumers increase their purchase intent when exogenously presented with positive signals about environmental, social, and—to a lesser extent—governance activities. Full ESG reports increase purchase intentions only for consumers who choose to view them. After the experiment, consumers increase their actual purchases, but these effects are small, short-lived, and only materialize for social signals and viewed ESG reports. Through a follow-up survey, we provide explanations for why consumers (do not) change their behavior after our experiment.
We show an analogue of the Klain-Schneider theorem for valuations that are invariant under rotations around a fixed axis, called zonal. Using this, we establish a new integral representation of zonal valuations involving mixed area measures with a disk. In our argument, we introduce an easy way to translate between this representation and the one involving area measures, yielding a shorter proof of a recent characterization by Knoerr. As applications, we obtain various integral geometric formulas for SO(n-1): an additive kinematic, a Kubota-, and a Crofton-type formula. This extends results by Hug, Mussnig, and Ulivelli. Finally, we provide a simpler proof of the integral representation of the mean section operators by Goodey and Weil. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
